Metsera (MTSR) Proxy Filing summary

Executive summary

• A special meeting is scheduled for November 13, 2025, for shareholders to vote on the amended merger agreement with Pfizer, which now offers $65.60 per share in cash and a contingent value right (CVR) of up to $20.65 per share, valuing the transaction at up to $86.25 per share.

• The amendment increased the cash consideration from $47.50 to $65.60 per share and raised the termination fee from $190 million to $265 million.

• The CVR payout structure was revised, reducing the maximum potential CVR payment and adjusting milestone amounts and deadlines.

• The board unanimously recommends voting in favor of the merger, citing enhanced value, speed, and certainty of closing, and the avoidance of significant legal and regulatory risks associated with a competing Novo Nordisk proposal.

• Regulatory clearance was obtained from the FTC for early termination of the HSR Act waiting period.

Voting matters and shareholder proposals

• Shareholders will vote on the adoption of the amended merger agreement and, if necessary, a proposal to adjourn the meeting to solicit additional proxies.

• Approval of the merger requires a majority of outstanding shares; failure to vote or abstentions count as votes against the merger.

Board of directors and corporate governance

• The board engaged in extensive negotiations with Pfizer and Novo Nordisk, ultimately determining Pfizer's offer provided the best value and certainty.

• The board considered multiple proposals and received financial analyses from its advisors before making its recommendation.

• Voting and support agreements were entered into with major shareholders and Pfizer.